132 related articles for article (PubMed ID: 35029761)
1. Dabrafenib monotherapy for a recurrent BRAFV600E-mutated TTF-1-positive posterior pituitary tumor.
Grenier-Chartrand F; Barrit S; Racu ML; Luce S; Spitaels J; Sadeghi-Meibodi N; Lebrun L; Salmon I; Lefranc F; De Witte O
Acta Neurochir (Wien); 2022 Mar; 164(3):737-742. PubMed ID: 35029761
[TBL] [Abstract][Full Text] [Related]
2. TTF-1 positive posterior pituitary tumor: Limitations of current treatment and potential new hope in BRAF V600E mutation variants.
Dawoud FM; Naylor RM; Giannini C; Swanson AA; Meyer FB; Uhm JH
Clin Neurol Neurosurg; 2020 Sep; 196():106059. PubMed ID: 32682222
[No Abstract] [Full Text] [Related]
3. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.
Rostami E; Witt Nyström P; Libard S; Wikström J; Casar-Borota O; Gudjonsson O
Acta Neurochir (Wien); 2017 Nov; 159(11):2217-2221. PubMed ID: 28918496
[TBL] [Abstract][Full Text] [Related]
4. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
Roque A; Odia Y
CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Dabrafenib for three children with brainstem BRAF
Philippe L; Maria K; Tariq A; Sofia M; Christine SM; Jean-Pierre F; Dudley RW; Sébastien P; Nada J; Valérie L
J Neurooncol; 2019 Oct; 145(1):135-141. PubMed ID: 31502039
[TBL] [Abstract][Full Text] [Related]
6. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C
J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157
[TBL] [Abstract][Full Text] [Related]
7. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
8. Dabrafenib in BRAFV600E mutant pilocytic astrocytoma in a pediatric patient.
Mustansir F; Mushtaq N; Darbar A
Childs Nerv Syst; 2020 Jan; 36(1):203-207. PubMed ID: 31418082
[TBL] [Abstract][Full Text] [Related]
9. Recurrent ganglioglioma in adults treated with BRAF inhibitors.
Chamberlain MC
CNS Oncol; 2016; 5(1):27-9. PubMed ID: 26680369
[TBL] [Abstract][Full Text] [Related]
10. Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with
Miller KE; Schieffer KM; Grischow O; Rodriguez DP; Cottrell CE; Leonard JR; Finlay JL; Mardis ER
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33637608
[TBL] [Abstract][Full Text] [Related]
11. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Cheng L; Jin Y; Liu M; Ruan M; Chen L
Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
[TBL] [Abstract][Full Text] [Related]
12. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF
White PS; Pudusseri A; Lee SL; Eton O
Thyroid; 2017 Sep; 27(9):1201-1205. PubMed ID: 28805135
[TBL] [Abstract][Full Text] [Related]
13. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
[TBL] [Abstract][Full Text] [Related]
14. BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.
Lim AM; Taylor GR; Fellowes A; Cameron L; Lee B; Hicks RJ; McArthur GA; Angel C; Solomon B; Rischin D
J Natl Compr Canc Netw; 2016 Mar; 14(3):249-54. PubMed ID: 26957611
[TBL] [Abstract][Full Text] [Related]
15. Significant response to dabrafenib in a patient with Erdheim-Chester disease with BRAFV600E mutation.
Verschelden G; Van Laethem J; Velkeniers B; Ilsen B; Noeparast A; De Grève J
Pol Arch Intern Med; 2018 Jun; 128(6):386-388. PubMed ID: 29968698
[No Abstract] [Full Text] [Related]
16. Dabrafenib: first global approval.
Ballantyne AD; Garnock-Jones KP
Drugs; 2013 Aug; 73(12):1367-76. PubMed ID: 23881668
[TBL] [Abstract][Full Text] [Related]
17. Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.
Nussbaum PE; Nussbaum LA; Torok CM; Patel PD; Yesavage TA; Nussbaum ES
J Clin Pharm Ther; 2022 Jun; 47(6):826-831. PubMed ID: 35023192
[TBL] [Abstract][Full Text] [Related]
18. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
19. Panniculitis Under Successful Targeted Inhibition of the MAPK/ERK Signaling Pathway in a Patient With BRAF V600E-mutated Spindle Cell Oncocytoma of the Pituitary Gland.
Sollfrank L; Lettmaier S; Erdmann M; Uslu U
Anticancer Res; 2019 Jul; 39(7):3955-3959. PubMed ID: 31262927
[TBL] [Abstract][Full Text] [Related]
20. Dabrafenib plus trametinib in patients with BRAF
Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
